Company: CRL
Filing Date: 2025-04-02
Form Type: DEF 14A
Source: 0001104659-25-030908
Chunk: 26

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-04-02
Form: DEF 14A
Chunk 26
---
 Form 10-K for the fiscal year ended December 28, 2024, for a discussion of the assumptions used by us in the Black-Scholes valuation model. As of December 28, 2024, each then current director held the aggregate number of option awards as follows: Dr. Andrews—8,825, Mr. Bertolini—8,252, Ms. Kemps-Polanco— 1,710, Dr. Kochevar—5,713, Mr. Llado—6,704, Dr. Mackay—8,182, Mr. Massaro—5,713 Dr. Thompson—3,572, Mr. Wallman—8,252, and Ms. Wilson—8,252. (5) None of our directors received perquisites or other personal benefits equal to or exceeding $10,000 in the aggregate. In 2024, we paid each non-employee director an annual base cash fee of $65,000 for service as our director. Members of the Audit Committee were paid an additional annual cash fee of $5,000 in recognition of the additional meetings the Audit Committee holds. Additional cash fees are paid to the Lead Director ($45,000), Chair of the Audit Committee ($25,000), Chair of the Compensation Committee ($20,000), Chair of the Corporate Governance and Nominating Committee ($20,000), Chair of the Finance Committee ($20,000), Chair of the Responsible Animal Use Committee ($20,000), Chair of the Science and Technology Committee ($20,000), and Chair of the Strategic Planning and Capital Allocation Committee ($20,000) for their added responsibilities. No additional fees are paid for attending meetings of the Board or any committee of the Board. We reimburse expenses incurred by directors in attending meetings of the Board of Directors and of its respective committees. The Board believes there is a greater opportunity for alignment of the Board’s compensation structure with the interests of the Company’s shareholders in creating sustained, long-term value by affording the Company’s independent directors the opportunity to receive all or a significant percentage of their compensation in the form of RSUs, with the ability to defer receipt of those RSUs for an extended period of time. Accordingly, (1) directors are permitted to elect in advance to receive their annual cash fees in the form of equivalent value RSUs; and (2) we have established the Charles River Laboratories International, Inc. Non-Employee Directors Deferral Plan, which allows directors, if they so choose, to defer receipt